AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $38,000.00 income · posted Jul 16, 2025

Lobbying activity 1

Health Issues

- ultrarare disease - newborn screening

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem